Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-04

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess the inoculation-related symptoms and long-term effects of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting. The investigators aim to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient

NCT02333474

Lung Neoplasms

COMPLETED PHASE1/PHASE2

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

NCT06168032

COVID-19 Recurrent Lung Cancer Vaccination +3 more

RECRUITING NA

Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells

NCT02084823

Neoplasms, Lung

COMPLETED PHASE1/PHASE2

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

NCT04286841

Immunotherapy Lung Cancer

RECRUITING

Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients

NCT06685653

NSCLC

NOT_YET_RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will enroll lung cancer/pulmonary nodule patients or healthy people who had undergone standard vaccination procedures against SARS-CoV-2/COVID-19. This observatory study will apply an electronic questionnaire to collect general information and post-vaccination symptoms or adverse events of vaccinated pulmonary nodules/lung cancer patients and healthy control. The researchers will further analyze whether the vaccine will promote the progression of primary tumors/pulmonary nodules through long-term follow-up. The investigators aim to assess the adverse events and long-term impact of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting, to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Pulmonary Nodule, Solitary Pulmonary Nodule, Multiple COVID-19 Pneumonia Vaccine Adverse Reaction SARS-CoV-2 Acute Respiratory Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated Case

Pulmonary nodules/lung cancer patients who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)

Vaccine inoculation against SARS-CoV-2

Intervention Type BIOLOGICAL

Inoculation with any type of approved vaccines according to the standard or recommended dose

Vaccinated Healthy Control

Healthy people who have been vaccinated against the SARS-CoV-2 (with any type/brand of vaccine)

Vaccine inoculation against SARS-CoV-2

Intervention Type BIOLOGICAL

Inoculation with any type of approved vaccines according to the standard or recommended dose

Unvaccinated Case

Pulmonary nodules/lung cancer patients who are not vaccinated against the SARS-CoV-2

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vaccine inoculation against SARS-CoV-2

Inoculation with any type of approved vaccines according to the standard or recommended dose

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Pulmonary nodule/lung cancer patients confirmed by CT or pathological examination, who have been vaccinated against the SARS-CoV-2
2. Pulmonary nodule/lung cancer patients confirmed by CT or pathological examination, who are not vaccinated against the SARS-CoV-2
3. Healthy people who have been vaccinated against the SARS-CoV-2